原发性肝癌的外科治疗进展

原发性肝癌是我国高发的恶性肿瘤之一,近年来其发病率有增高趋势,统计表明我国肝癌的年死亡率为20.40/10万,其中城市为19.98/10万,农村为23.59/10万,分别占恶性肿瘤死亡率的第二和第一位.全世界每年新发病例约45%在我国大陆,尤以东南沿海区域高发的趋势更为严峻,发病年龄趋于年轻.

A Comparative Study of the Expressions of ets-2, IGF-Ⅱ,C-myc and N-ras in Human Primary Hepatocellular Carcinoma and Tumor-adjacent Tissues

The expressions of ets-2 ,IGF-Ⅱ,C-myc and N-ras in 12 pairs ofhuman primary hepatocellular carcinoma(PHC)and tumor-adjacent tissues are presentedin this paper.The results showed that there was at least one of the four oncogenesstudied over-expressed in the 12 pairs of samples.Ets-2 was the most commonly ex-pressed oncogene seen in all the PHC and tumor-adjacent tissues,with 3.5 and 2.4 Kb asthe major two bands,which are different from the evenly expressed 4.5 ,3.5 and 2.4 Kbbands in the normal control livers.In 6 tumor-adjacent tissues,the expression ofets-2 was higher than that in PHC.IGF-Ⅱ was expressed as 5.0 and 2.0 Kb fetaltranscripts in PHC and tumor-adjacent tissues,while in the normal control livers thetranscript was 5.6 Kb only.In one tumor-adjacent tissue there were IGF-Ⅱ fetal tran-scripts ,but in the corresponding PHC no IGF-Ⅱ transcripts were detected .N-raswas expressed as 4.0 kb band in 8 out of 12 PHC and in 6 out of 12 tumor-adjacent tis-sues.In two cases the expression of N-ras was higher in tumor-adjacent tissues than inPBC.5.6 and 2.6 Kb N-ras transcripts were also detected in one pair of PHC and tumor-adjacent tissues and in two tumor-adjacent tisues only,together with the 4.0 Kbtranscript.C-myc was expressed as 4.0 Kb band in 9 out of 12 PHC and in 6 out of12 tumor-adjacent tissues.One tumor-adjacent tissue had higher C-myc expression thanPHC In two PHC ,a 2.2 Kb C-myc transcript was also detected.The roles and rela-tionships of these oncogenes in the carcinogenesis of human PHC are discussed.

肝细胞癌患者微波消融联合化疗栓塞术前的抗病毒治疗

目的：研究肝细胞癌（ HCC）行经皮肝穿刺肝肿瘤微波消融术（ PMWA）联合经导管化疗栓塞术（ TACE）治疗后乙型肝炎病毒（ HBV）再激活的临床特点以及联合治疗前抗病毒治疗对HBV再激活的影响。方法根据术前是否行抗病毒治疗180例接受PMWA联合TACE的HCC患者，分为抗病毒治疗组（A组，n＝90）和对照组（B组，n＝90）。观察两组患者接受联合疗法前后HBV-DNA变化，了解联合疗法前后的HBV再激活情况及抗病毒治疗对HBV再激活的影响。结果抗病毒治疗组联合疗法后的HBV再激活率显著低于对照组[8．2％（7／90）比20．0％（18／90），P＜0．05]。联合疗法术前HBV DNA＞104 copies／ml是导致HBV再激活的唯一的独立危险因素（ P＜0.05）。结论HBV表面抗原携带者接受联合疗法术后具有较高的HBV再激活率，而抗病毒治疗能够显著降低HBV再激活率。因此，对HBV DNA＞104 copies／ml的患者应在联合疗法术前进行抗病毒治疗。

人间一甲子 岁月始更新

我今年90岁，耳不聋眼不花。让人十分惊奇。对我不仅要处理全院的工作，还要看病、开刀．人们更是感到不可思议。在一般人的观念中．花甲之后便是老态龙钟的开始，七老八十了，那就更准备划上“休止符”吧。可是，我今天要对读者朋友们说：六十一甲子，六十一轮回，你活过了六十岁．新的生命就又开始了——60岁是“少儿”．